| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2019-12-23 |
| タイトル |
|
|
タイトル |
Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| 著者 |
野津, 司
宮岸, 沙織
野津, 麟太郎
高草木, 薫
奥村, 利勝
|
| 著者 ローマ字 |
|
|
|
Nozu, Tsukasa |
| 著者 ローマ字 |
|
|
|
Miyagishi, Saori |
| 著者 ローマ字 |
|
|
|
Nozu, Rintaro |
| 著者 ローマ字 |
|
|
|
Takakusaki, Kaoru |
| 著者 ローマ字 |
|
|
|
Okumura, Toshikatsu |
| 書誌情報 |
Scientific reports
巻 9,
号 1,
p. 19603,
発行日 2019-12-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2045-2322 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1038/s41598-019-56132-4 |
| 識別番号 その他 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
PMID：31862976 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Lipopolysaccharide (LPS) or repeated water avoidance stress (WAS) induces visceral allodynia and gut hyperpermeability via corticotropin-releasing factor (CRF) and proinflammatory cytokines, which is a rat irritable bowel syndrome (IBS) model. As butyrate is known to suppress the release of proinflammatory cytokine, we hypothesized that butyrate alleviates these colonic changes in IBS models. The visceral pain was assessed by electrophysiologically measuring the threshold of abdominal muscle contractions in response to colonic distention. Colonic permeability was determined by measuring the absorbance of Evans blue in colonic tissue. Colonic instillation of sodium butyrate (SB; 0.37-2.9 mg/kg) for 3 days inhibited LPS (1 mg/kg)-induced visceral allodynia and colonic hyperpermeability dose-dependently. Additionally, the visceral changes induced by repeated WAS (1 h for 3 days) or CRF (50 µg/kg) were also blocked by SB. These effects of SB in the LPS model were eliminated by compound C, an AMPK inhibitor, or GW9662, a PPAR-γ antagonist, NG-nitro-L-arginine methyl ester, a NO synthesis inhibitor, naloxone or sulpiride. SB attenuated visceral allodynia and colonic hyperpermeability in animal IBS models. These actions may be AMPK and PPAR-γ dependent and also mediated by the NO, opioid and central dopamine D2 pathways. Butyrate may be effective for the treatment of IBS. |
| 資源タイプ |
|
|
内容記述タイプ |
Other |
|
資源タイプ |
text |
| 著者版フラグ |
|
|
出版タイプ |
AM |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
| ID(XooNIps) |
|
|
|
31862976 |
| 閲覧数(XooNIps) |
|
| ダウンロード数(XooNIps) |
|
|
|
330 |
7340.pdf (2.5 MB)
